tenofovir disoproxil fumarate

URI: https://gptkb.org/entity/tenofovir_disoproxil_fumarate

GPTKB entity

Statements (51)

Predicate	Object
gptkbp:instanceOf	antiviral drug prodrug
gptkbp:administeredBy	oral tablet oral powder
gptkbp:approvalYear	2001
gptkbp:approvedBy	gptkb:FDA
gptkbp:ATCCode	J05AF07
gptkbp:bioavailability	25% (fasted), 39% (fed)
gptkbp:brand	gptkb:Viread
gptkbp:CASNumber	202138-50-9
gptkbp:chemicalFormula	C19H30N5O10P·C4H4O4
gptkbp:combinationTherapy	gptkb:efavirenz gptkb:elvitegravir gptkb:rilpivirine gptkb:cobicistat gptkb:lamivudine gptkb:alafenamide emtricitabine
gptkbp:contraindication	severe renal impairment
gptkbp:developedBy	gptkb:Gilead_Sciences
gptkbp:eliminationHalfLife	17 hours
gptkbp:excretion	renal
gptkbp:firstSynthesized	1990s
https://www.w3.org/2000/01/rdf-schema#label	tenofovir disoproxil fumarate
gptkbp:includes	gptkb:WHO_Model_List_of_Essential_Medicines gptkb:PEPFAR_program
gptkbp:KEGGID	gptkb:D02141
gptkbp:legalStatus	prescription only
gptkbp:mechanismOfAction	nucleotide reverse transcriptase inhibitor
gptkbp:metabolism	tenofovir
gptkbp:molecularWeight	635.5 g/mol (tenofovir disoproxil); 914.9 g/mol (fumarate salt)
gptkbp:patent_expiration_(US)	2017
gptkbp:pregnancyCategory	B B1
gptkbp:proteinBinding	<1%
gptkbp:PubChem_CID	gptkb:CHEMBL1201197 6398764 DB00300
gptkbp:routeOfAdministration	oral
gptkbp:sideEffect	renal impairment decreased bone mineral density
gptkbp:synonym	gptkb:TDF gptkb:tenofovir_DF gptkb:tenofovir_disoproxil_fumarate_ester
gptkbp:UNII	JX5OHT5B5K
gptkbp:usedFor	HIV infection chronic hepatitis B
gptkbp:WHOModelListOfEssentialMedicines	yes
gptkbp:bfsParent	gptkb:NRTIs gptkb:pre-exposure_prophylaxis_(PrEP)
gptkbp:bfsLayer	5